IMMURON LTD/S (NASDAQ:IMRN) Short Interest Update

Share on StockTwits

IMMURON LTD/S (NASDAQ:IMRN) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totalling 10,100 shares, a drop of 17.9% from the August 31st total of 12,300 shares. Based on an average daily volume of 1,760,000 shares, the days-to-cover ratio is currently 0.0 days.

Separately, ValuEngine lowered IMMURON LTD/S from a “buy” rating to a “hold” rating in a research note on Tuesday, June 9th.

A hedge fund recently bought a new stake in IMMURON LTD/S stock. Virtu Financial LLC acquired a new stake in shares of IMMURON LTD/S (NASDAQ:IMRN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 32,961 shares of the company’s stock, valued at approximately $245,000. Virtu Financial LLC owned about 0.60% of IMMURON LTD/S as of its most recent filing with the Securities and Exchange Commission. 0.61% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ IMRN traded down $0.28 on Friday, reaching $7.05. 33,454 shares of the stock traded hands, compared to its average volume of 1,238,899. The firm’s fifty day simple moving average is $8.65 and its 200 day simple moving average is $5.91. IMMURON LTD/S has a 12 month low of $1.55 and a 12 month high of $28.99.

About IMMURON LTD/S

Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments.

Featured Article: Capital Gains Distribution

Receive News & Ratings for IMMURON LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMURON LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply